Evaluation of the Effectiveness of Prophylactic Low Molecular Weight Heparin by Thromboelastography in Patients Who Underwent Lobectomy Due to Malignancy
Overview
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Ege University
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- r time
Overview
Brief Summary
This study aims to evaluate the necessity and effectiveness of using low molecular weight heparin (LMWH) for prophylaxis in the postoperative period in patients who underwent lobectomy due to malignancy, using thromboelastography.Blood samples taken from the patients before low molecular weight heparin prophylaxis (preoperative), before prophylaxis in the postoperative period (postoperative day 1) and after the start of postoperative prophylaxis (postoperative day 3) will be examined by thromboelastography.
Detailed Description
General characteristics of the patients such as age, gender, presence of comorbidities, smoking, type of operation and approach applied, operation duration, TEG measurements and postoperative complication development were recorded with case forms.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients who underwent lobectomy with thoracotomy or videothoracoscopy (VATS) due to malignancy (primary or secondary lung cancer)
Exclusion Criteria
- •Patients with a known diagnosis of bleeding or coagulation disorders
- •Patients receiving anticoagulant and antiplatelet therapy in the preoperative period
- •Patients who developed perioperative bleeding and therefore underwent perioperative blood and blood product replacement
Outcomes
Primary Outcomes
r time
Time Frame: 24 months
'r time' value measured by thromboelastography
angle a
Time Frame: 24 months
'angle a' value measured by thromboelastography
k time
Time Frame: 24 months
'k time' value measured by thromboelastography
maximum amplitude (MA)
Time Frame: 24 months
'MA' value measured by thromboelastography
Secondary Outcomes
- complications(24 months)
Investigators
Gizem Kececi Ozgur
Principal investigator
Ege University